JP2016527202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527202A5 JP2016527202A5 JP2016519586A JP2016519586A JP2016527202A5 JP 2016527202 A5 JP2016527202 A5 JP 2016527202A5 JP 2016519586 A JP2016519586 A JP 2016519586A JP 2016519586 A JP2016519586 A JP 2016519586A JP 2016527202 A5 JP2016527202 A5 JP 2016527202A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- compound
- cancer
- administration
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 10
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 8
- 239000003207 proteasome inhibitor Substances 0.000 claims 8
- 238000003384 imaging method Methods 0.000 claims 6
- 238000002600 positron emission tomography Methods 0.000 claims 5
- 108091006300 SLC2A4 Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- -1 peptidyl boronic acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000003325 tomography Methods 0.000 claims 3
- 229960001467 bortezomib Drugs 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 108010064641 ONX 0912 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 229960002951 ixazomib citrate Drugs 0.000 claims 1
- MBOMYENWWXQSNW-AWEZNQCLSA-N ixazomib citrate Chemical compound N([C@@H](CC(C)C)B1OC(CC(O)=O)(CC(O)=O)C(=O)O1)C(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MBOMYENWWXQSNW-AWEZNQCLSA-N 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 claims 1
- 229950005750 oprozomib Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960005311 telbivudine Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361833186P | 2013-06-10 | 2013-06-10 | |
| US61/833,186 | 2013-06-10 | ||
| PCT/US2014/041643 WO2014200969A2 (en) | 2013-06-10 | 2014-06-10 | Methods of treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016527202A JP2016527202A (ja) | 2016-09-08 |
| JP2016527202A5 true JP2016527202A5 (OSRAM) | 2017-07-20 |
Family
ID=52022914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519586A Pending JP2016527202A (ja) | 2013-06-10 | 2014-06-10 | 癌の治療方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170035917A1 (OSRAM) |
| EP (1) | EP3008212A4 (OSRAM) |
| JP (1) | JP2016527202A (OSRAM) |
| WO (1) | WO2014200969A2 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3046566B1 (en) | 2013-09-19 | 2020-12-02 | The Research Foundation for The State University of New York | Methods and materials for treating liver steatosis |
| CA2981138A1 (en) | 2015-03-27 | 2016-10-06 | The Research Foundation For The State University Of New York | Methods and materials for reducing amyloid beta levels within a mammal |
| US20180078599A1 (en) * | 2015-03-27 | 2018-03-22 | The Research Foundation For The State University Of New York | Methods and materials for treating cancer |
| US12287389B1 (en) * | 2015-07-31 | 2025-04-29 | Fonar Corporation | Method and system for monitoring effectiveness of a treatment regimen |
| BR112019011186A2 (pt) | 2016-12-01 | 2019-10-08 | Regeneron Pharmaceuticals, Inc. | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. |
| CN110650974B (zh) | 2017-02-10 | 2024-04-19 | 瑞泽恩制药公司 | 用于免疫-pet成像的放射性标记的抗-lag3抗体 |
| JP7304846B2 (ja) | 2017-07-24 | 2023-07-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｃｄ８抗体およびその使用 |
| EP3793614A4 (en) | 2018-04-30 | 2022-04-20 | Integral Molecular, Inc. | GLUCOSE TRANSPORTER-4 ANTIBODIES, PROCESSES FOR THEIR PRODUCTION AND THEIR USES |
| CN109053782B (zh) * | 2018-08-09 | 2020-01-17 | 潍坊博创国际生物医药研究院 | 多功能靶向免疫小分子抗癌药枸橼酸Bestazomib及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100111856A1 (en) * | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP2730580A1 (en) * | 2008-06-17 | 2014-05-14 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
| AU2011293522B2 (en) * | 2010-08-24 | 2015-03-19 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| CN103282343A (zh) * | 2010-09-21 | 2013-09-04 | 通用电气健康护理有限公司 | 作为放射性示踪剂的胆碱类似物 |
| CA2820384A1 (en) * | 2010-12-06 | 2012-06-14 | Cure Cancer Worldwide Corporation | Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer |
| WO2013028907A1 (en) * | 2011-08-23 | 2013-02-28 | Infinity Pharmaceuticals, Inc. | Biomarkers predictive of therapeutic responsiveness to hsp90 inhibitors and uses thereof |
| CN108383893A (zh) * | 2011-08-30 | 2018-08-10 | 塔夫茨大学信托人 | 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂 |
| CA2855356A1 (en) * | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
-
2014
- 2014-06-10 EP EP14810471.4A patent/EP3008212A4/en not_active Withdrawn
- 2014-06-10 US US14/896,013 patent/US20170035917A1/en not_active Abandoned
- 2014-06-10 WO PCT/US2014/041643 patent/WO2014200969A2/en not_active Ceased
- 2014-06-10 JP JP2016519586A patent/JP2016527202A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527202A5 (OSRAM) | ||
| US11730736B2 (en) | Anticancer agents | |
| JP2014510728A5 (OSRAM) | ||
| JP2015536964A5 (OSRAM) | ||
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2010270124A5 (OSRAM) | ||
| RU2019142507A (ru) | Композиции, способы и системы для синтеза и применение визуализирующих средств | |
| JP2015212268A5 (OSRAM) | ||
| JP2014515373A5 (OSRAM) | ||
| KR20160006668A (ko) | 브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물 | |
| JP2018184465A5 (OSRAM) | ||
| JP2014513089A5 (OSRAM) | ||
| JP2012255026A5 (OSRAM) | ||
| CN105452258B (zh) | 使用双核金(i)化合物用于癌症治疗的方法 | |
| JP2018508516A5 (OSRAM) | ||
| JP2018035162A5 (OSRAM) | ||
| JP2011529968A5 (OSRAM) | ||
| CN108289960A (zh) | Ep4受体拮抗剂用于治疗nash相关肝癌的用途 | |
| MX2013013014A (es) | Metodo para el tratamiento de tumores solidos avanzados. | |
| JP2015522033A5 (OSRAM) | ||
| JP2014512355A5 (OSRAM) | ||
| CN110433165A (zh) | Akt和mek抑制剂化合物的组合及其使用方法 | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2014530181A5 (OSRAM) | ||
| TW201141472A (en) | Method to treat small cell lung cancer |